Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Salvage Chemotherapy (R-ESHAP) to Treat Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of aggressive non-Hodgkin's lymphoma~* Refractory to the first line chemotherapy or relapsed~* Expression of CD20 on lymphoma cells~* Measurable lesions on imaging studies~Exclusion Criteria:~* Blood cell counts not reaching to 3,000/microliter for white blood cells, 7 g/dl for hemoglobin, and 50,000/microliter for platelets without transfusion at the time of registration~* Circulating lymphoma cells equal to or more than 25,000/microliter~* Hepatic dysfunction~* Renal insufficiency~* Cardiac dysfunction or arrhythmia~* Sever infection (bacterial, viral)~* CNS involvement~* Other malignancies~* Pregnancy or breast feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).